Previous close | 1.6000 |
Open | 1.5500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 45.00 |
Expiry date | 2026-01-16 |
Day's range | 1.5000 - 1.6500 |
Contract range | N/A |
Volume | |
Open interest | N/A |
(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster COVID-19 vaccine Spikevax and RSV shot mResvia. According to the two lawsuits, Moderna's lipid nanoparticles for transporting fragile mRNA into the human body infringe several GSK patents covering similar innovations. GSK filed a related lawsuit against Pfizer and BioNTech in the same court in April over their COVID-19 vaccine.
We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other super micro computer stocks. As earnings season kicks off, Mad Money’s host, Jim Cramer reminds investors that bad news can often be […]
The latest investor updates on stocks that are trending on Thursday.